Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2003–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $438442 | $6M | $5M | $5M | $7M | $1.2B | $1.8B | — | — | — | — |
| Enterprise Value | $10M | $19M | $23M | $17M | $16M | $1.2B | $1.8B | — | — | — | — |
| P/E Ratio → | -0.08 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.01 | 0.11 | 0.10 | 0.09 | 0.12 | 34.84 | 113.60 | — | — | — | — |
| P/B Ratio | — | — | 1.74 | 0.33 | 0.28 | 5.79 | 143.15 | — | — | — | — |
| P/FCF | 0.13 | 1.25 | — | — | — | — | — | — | — | — | — |
| P/OCF | 0.13 | 1.25 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.36 | 0.42 | 0.34 | 0.29 | 35.29 | 113.10 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 2360.97 | — | — | — | — | — |
| EV / FCF | — | 4.13 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.7% | 17.7% | 15.6% | 20.2% | 16.9% | 18.6% | 65.9% | 43.3% | 80.8% | 63.8% | — |
| Operating Margin | -21.2% | -21.2% | -18.9% | -26.2% | -56.7% | -67.6% | -51.9% | -113.2% | 59.3% | -2.8% | — |
| Net Profit Margin | -20.7% | -20.7% | -19.6% | -19.5% | -347.6% | -52.2% | -180.6% | -80.4% | 32.4% | 12.2% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -125.7% | -50.7% | -165.2% | -16.3% | -148.2% | -56.3% | — | — | — |
| ROA | -31.9% | -31.9% | -24.1% | -17.3% | -108.5% | -10.9% | -83.2% | -47.2% | 7294.2% | 11423.7% | -5706.5% |
| ROIC | -57.5% | -57.5% | -33.4% | -32.8% | -18.2% | -15.4% | -68.9% | -118.7% | — | — | — |
| ROCE | -1158.7% | -1158.7% | -101.1% | -59.7% | -23.4% | -17.2% | -27.4% | -73.2% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 5.73 | 1.01 | 0.48 | 0.14 | 0.08 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 0.85 |
| Net Debt / Equity | — | — | 5.45 | 0.87 | 0.38 | 0.07 | -0.63 | -0.49 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -0.01 | — | 0.83 |
| Debt / FCF | — | 2.88 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.23 | -3.23 | -1.86 | -1.58 | -12.22 | 0.76 | -0.39 | -9.37 | — | — | -30.50 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.67 | 0.67 | 0.67 | 0.74 | 0.97 | 1.58 | 4.33 | 9.31 | 0.15 | 0.02 | 0.00 |
| Quick Ratio | 0.54 | 0.54 | 0.58 | 0.44 | 0.48 | 0.98 | 2.98 | 7.21 | 0.15 | 0.02 | 0.00 |
| Cash Ratio | 0.08 | 0.08 | 0.02 | 0.06 | 0.07 | 0.27 | 1.42 | 5.34 | 0.15 | 0.01 | 0.00 |
| Asset Turnover | — | 1.72 | 1.38 | 1.00 | 0.90 | 0.12 | 0.42 | 0.29 | 140.45 | 480.48 | — |
| Inventory Turnover | 10.55 | 10.55 | 14.18 | 3.91 | 2.72 | 0.89 | 0.64 | 0.94 | — | — | — |
| Days Sales Outstanding | — | 86.54 | 112.67 | 84.74 | 70.66 | 334.25 | 131.34 | 82.86 | 0.87 | 0.43 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 79.8% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $4M | $2M | $2M | $1M | $6M | $4M | $4M | $3M | $53979 | $51650 |
Liquidity and Solvency Risk
Based on reported figures, IMCC trades at a P/S ratio of 0.01, a valuation level that suggests the market is pricing the company as a distressed asset rather than a growth-oriented entity, reflecting deep skepticism regarding its ability to achieve sustainable profitability in the competitive medical cannabis sector.
The lack of meaningful P/E or EV/EBITDA multiples underscores the absence of positive earnings and the market's focus on survival rather than growth. Investors should interpret this valuation as a reflection of the company's high-risk profile and the significant uncertainty surrounding its future cash-generating capabilities.
As reported in financial statements, the company's ROIC has remained consistently negative, reaching -9.9% in 2026Q1, which indicates that the firm is currently destroying shareholder value rather than compounding it through its core operations in the Israeli and German medical cannabis markets.
The persistent inability to generate a positive return on invested capital suggests that the company's cost of capital significantly exceeds its operational returns. This trend warrants further investigation into whether the current business model can ever reach a scale that justifies the capital deployed to maintain its distribution infrastructure.
According to recent quarterly data, the cash conversion cycle has fluctuated significantly, reaching 24 days in 2026Q1, which masks underlying inefficiencies in inventory management and the company's reliance on extended payment terms from suppliers to manage its limited liquidity position.
The high DSO of 143 days suggests that the company faces challenges in collecting receivables, which puts additional pressure on its already constrained cash flow. This inefficiency appears to be a structural hurdle that limits the company's ability to reinvest in its core German distribution bridge.
Based on the latest balance sheet, the current ratio of 0.55 in 2026Q1 indicates that the company lacks sufficient liquid assets to cover its short-term obligations, a situation that appears increasingly precarious given the ongoing net losses and the lack of access to traditional debt markets.
The quick ratio of 0.47 further highlights the company's dependence on inventory liquidation to meet immediate cash needs, which is a high-risk strategy in a volatile market. Investors should monitor this liquidity position closely, as it may necessitate further dilutive equity raises to avoid a default scenario.
Analysts frequently misapply revenue-based valuation multiples to IMCC, failing to account for the fact that the company's top-line figures are heavily influenced by low-margin wholesale procurement rather than high-margin proprietary production, which obscures the true underlying earning power of the business.
Using P/S ratios in this context is misleading because it ignores the significant cost of goods sold associated with the company's import-heavy business model. A more appropriate metric would be a gross-profit-based valuation or an analysis of contribution margins per unit, which would better reflect the company's actual ability to generate cash from its German distribution network.
Includes 30+ ratios · 23 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IMCC stock.
IM Cannabis Corp.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Based on historical data, IM Cannabis Corp. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
IM Cannabis Corp. has 17.7% gross margin and -21.2% operating margin.